Why did GAAP EPS grow so much faster than adjusted EPS?

GAAP EPS growth of 76.1% was flattered by a low prior-year base. The prior-year quarter included a $214.0 million opioid-related litigation accrual, which depressed GAAP earnings. Adjusted EPS growth of 16.3% is a better guide to ongoing operating performance, while the current GAAP quarter also includes a $198.6 million antitrust settlement gain that partly offsets acquisition amortization and integration charges.

How significant is the Retina Consultants of America acquisition to results and the balance sheet?

RCA, acquired in January 2025, contributed to gross margin expansion and higher operating expenses. It was financed with $1.8 billion of senior notes and a $1.5 billion term loan, raising long-term debt to about $7.1 billion from $3.8 billion at September 30, 2024. Goodwill and intangibles increased to $18.0 billion from $13.3 billion. Investors should watch the impact of higher interest costs and integration progress. Note that the 15% equity retained by RCA physicians and management is treated as a contingent liability rather than a noncontrolling interest, so it does not reduce EPS guidance.

Is the raised guidance driven by sustainable growth?

The raise is attributed to stronger earnings growth in U.S. Healthcare Solutions, which benefits from market growth in specialty and GLP-1 products and from the RCA acquisition. Guidance also reflects lower expectations for International Healthcare Solutions, where revenue growth was cut to 3%-4%. Because the guidance is adjusted (non-GAAP) and excludes items such as antitrust gains and LIFO effects, investors should assess how much of the increase depends on the timing of settlements and inflation-related inventory effects.

What are the main risks highlighted by the quarter's results?

Key risks include reliance on the timing of antitrust litigation settlement gains, LIFO expense volatility tied to pharmaceutical price inflation, weakness in the International segment (operating income down 17.3%, with foreign currency translation headwinds), and higher leverage and interest expense following the RCA financing. The company's shareholder return is supported by a $0.55 dividend and buybacks, but cash generation for the six months was modest relative to net income.

COR 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.

Cencora (COR) reported fiscal Q2 2025 results (quarter ended March 31, 2025) with revenue of $75.5 billion^a, up 10.3% year-over-year, driven by an 11.4% increase in U.S. Healthcare Solutions revenue, including GLP-1 and specialty product volume growth.

GAAP diluted EPS was $3.68^b (vs. $2.09 a year earlier, up 76.1%), while adjusted diluted EPS rose 16.3% to $4.42. GAAP results were boosted by a $198.6 million gain from antitrust litigation settlements, which investors should weigh as non-recurring, and were reduced by acquisition-related amortization, integration costs, and restructuring charges. Operating income rose 87.3% on a GAAP basis to $1.0 billion, while adjusted operating income grew 15.3% to $1.2 billion.

Management raised its fiscal 2025 adjusted diluted EPS guidance to $15.70^c-$15.95 from $15.30-$15.60, reflecting stronger U.S. Healthcare Solutions earnings growth (segment operating income growth now 17.5%-19.5%, up from 14.5%-16.5%). Partly offsetting this, International Healthcare Solutions guidance was lowered, with reported segment operating income now expected to decline 1% to 4%. Results were affected by the January 2025 acquisition of Retina Consultants of America (RCA), which lifted gross margin and operating expenses and substantially increased debt, funded by $1.8 billion of senior notes and a $1.5 billion term loan.

Net debt and other long-term liabilities rose meaningfully, and total equity increased to $1.18 billion^d, which investors should monitor against higher interest expense, which rose 62.2% to $104 million in the quarter. The company also declared a quarterly dividend of $0.55 per share, payable June 2, 2025, and reduced diluted share count by 3.0% year-over-year through buybacks. Cash flow from operations was modest for the six-month period at $632.5 million, down from prior-year levels in that period's cash flow presentation, with adjusted free cash flow of $176.0 million, reflecting working capital outflows and acquisition spending.

02—Key points

Key Highlights

Revenue rose 10.3% year-over-year to $75.5 billion, led by an 11.4% increase in U.S. Healthcare Solutions to $68.3 billion, driven by volume growth including GLP-1 products.
GAAP diluted EPS was $3.68, up 76.1% from $2.09; adjusted diluted EPS was $4.42, up 16.3% from $3.80.
GAAP results include a $198.6 million gain from antitrust litigation settlements, which is non-recurring and excluded from adjusted results.
Fiscal 2025 adjusted diluted EPS guidance raised to $15.70-$15.95 from $15.30-$15.60, with U.S. segment operating income growth guidance raised to 17.5%-19.5%.
International Healthcare Solutions revenue grew only 0.7% (5.7% constant currency), and segment operating income fell 17.3%; full-year reported segment operating income is now expected to decline 1%-4%.
Interest expense rose 62.2% to $104.0 million, reflecting debt raised to fund the January 2025 Retina Consultants of America acquisition.
Quarterly dividend of $0.55 per share declared, payable June 2, 2025; diluted share count fell 3.0% year-over-year on share repurchases.

03—Questions

Frequently Asked Questions

Why did GAAP EPS grow so much faster than adjusted EPS?
GAAP EPS growth of 76.1% was flattered by a low prior-year base. The prior-year quarter included a $214.0 million opioid-related litigation accrual, which depressed GAAP earnings. Adjusted EPS growth of 16.3% is a better guide to ongoing operating performance, while the current GAAP quarter also includes a $198.6 million antitrust settlement gain that partly offsets acquisition amortization and integration charges.
How significant is the Retina Consultants of America acquisition to results and the balance sheet?
RCA, acquired in January 2025, contributed to gross margin expansion and higher operating expenses. It was financed with $1.8 billion of senior notes and a $1.5 billion term loan, raising long-term debt to about $7.1 billion from $3.8 billion at September 30, 2024. Goodwill and intangibles increased to $18.0 billion from $13.3 billion. Investors should watch the impact of higher interest costs and integration progress. Note that the 15% equity retained by RCA physicians and management is treated as a contingent liability rather than a noncontrolling interest, so it does not reduce EPS guidance.
Is the raised guidance driven by sustainable growth?
The raise is attributed to stronger earnings growth in U.S. Healthcare Solutions, which benefits from market growth in specialty and GLP-1 products and from the RCA acquisition. Guidance also reflects lower expectations for International Healthcare Solutions, where revenue growth was cut to 3%-4%. Because the guidance is adjusted (non-GAAP) and excludes items such as antitrust gains and LIFO effects, investors should assess how much of the increase depends on the timing of settlements and inflation-related inventory effects.
What are the main risks highlighted by the quarter's results?
Key risks include reliance on the timing of antitrust litigation settlement gains, LIFO expense volatility tied to pharmaceutical price inflation, weakness in the International segment (operating income down 17.3%, with foreign currency translation headwinds), and higher leverage and interest expense following the RCA financing. The company's shareholder return is supported by a $0.55 dividend and buybacks, but cash generation for the six months was modest relative to net income.

04—Continue

← View all 8-K filings